Devita, Hellman, and Rosenberg's Cancer

LWBK1006-08 LWW-Govindan-Review December 12, 2011 18:49

Chapter 8•Principles of Medical Oncology 97

Question 8.12. In early-stage colon cancer treated with adjuvant chemotherapy, the

majority of relapses occur:

A. Within the first 5 years

B. Within the first 3 years

C. Within the first 2 years

D. Within the first year

Question 8.13. Gompertzian kinetics are characterized by:

A. Clinically undetectable tumors are at their lowest growth fraction.

B. The growth fraction is stable over time.

C. The growth fraction increases exponentially with time.

D. The growth fraction decreases exponentially with time.

Question 8.14. In patients with activating mutations in the tyrosine kinase (TK) domain

of EGFR, all of the following genetic changes are associated with devel-

opment of resistance to tyrosine kinase inhibitors (TKI), EXCEPT:

A. T790M mutation

B. Loss of PTEN expression

C. D761Y mutation

D. MET gene mutation

Question 8.15. All of the following are true regarding an intermittent treatment approach,

EXCEPT:

A. Salvage therapies should show a good response.

B. Sufficient time is needed between the termination of induction

chemotherapy and progressive disease.

C. A majority of responses should be achieved during the induction

chemotherapy period.

D. Reinitiation of the induction chemotherapy is not indicated.

Question 8.16. In patients with colorectal cancer the genetic change associated with resis-

tance to cetuximab is:

A. BRAF mutation

B. Wild-type Kras

C. EGFR-TK mutation

D. NFB activation

Question 8.17. Dose-dense chemotherapy was developed after the observation that:

A. The growth of cells is significantly lower in the early part of the

growth curve.

B. The log cell kill is higher in smaller volume tumors, resulting in more

rapid growth between chemotherapy cycles.

C. Growth between chemotherapy cycles is halted.

D. More frequent administration of chemotherapy led to less toxicity.